ESMO Symposium on Immuno-Oncology 2016

Oncology Meeting Resources

04 Nov - 06 Nov, Lausanne, Switzerland

ESMO Immuno Oncology 2016 Square

ESMO Symposium on Immuno-Oncology 2016 underlined ESMO’s commitment to educate cancer physicians and researchers in a rapidly evolving area of treating cancer through immunotherapy and offered an update on the latest developments in immuno-oncology in an effort to bring innovative approaches directly to patients.

Abstracts, presentations and webcasts from the ESMO Symposium on Immuno-Oncology 2016 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
Ali Unal 8PD - Dendritic cell production from allogenenic donor Cd34+ stem cells and mononuclear cells: Cancer vaccine Poster discussion session
Verena Wieser 9PD - PD-1 and PD-L1 expression in ovarian cancer Poster discussion session
Marie Westergaard 54PD - Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer Poster discussion session
Robert Andtbacka Invited discussant abstracts 6PD, 7PD, 8PD, 9PD and 54PD Poster discussion session
Sean Hall 10PD - Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC Poster discussion session
Else Marit Inderberg 11PD - Tapping CD4 T cells for cancer immunotherapy Poster discussion session
Christoph Esslinger 12PD - MemoMAB, a novel technology for the banking and screening of cognate human immunoreceptor repertoires Poster discussion session
Inge-Marie Svane Invited discussant abstracts 10PD, 11PD and 12PD Poster discussion session
Valerio Nardone 13P - Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy Lunch and general poster viewing
Nicola Gaynor 14P - The effector capacity of peripheral blood mononuclear cells (PBMCs) from HER2+ breast cancer (BC) patients treated with chemotherapy and HER2-targeted therapies (ICORG 10-05) Lunch and general poster viewing
Anders Høgset 15P - Clinical validation of photochemical internalisation (fimaVacc) – A novel technology for enhancing cellular immune responses to peptide- and protein-based therapeutic cancer vaccines Lunch and general poster viewing
Younghoon Kim 16P - Prognostic value of immune cells within colorectal cancer are determined by analyzing subset densities of tumor associated macrophage and tumor infiltrating lymphocytes Lunch and general poster viewing
Michal Stanczak 17P - Upregulation of self-associated molecular patterns and Siglec receptors on T cells facilitate cancer immune evasion Lunch and general poster viewing
Lenka Zdrazilova Dubska 18P - TKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation Lunch and general poster viewing
Barbara Volz 19P - Immunomodulation and inhibition of tumor growth by a new class of TLR9 agonists – EnanDIM Lunch and general poster viewing